Medlab Clinical Valuation

Is MDC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MDC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MDC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDC's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDC?

Key metric: As MDC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MDC. This is calculated by dividing MDC's market cap by their current revenue.
What is MDC's PS Ratio?
PS Ratio9.8x
SalesAU$1.54m
Market CapAU$15.07m

Price to Sales Ratio vs Peers

How does MDC's PS Ratio compare to its peers?

The above table shows the PS ratio for MDC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.4x
ATH Alterity Therapeutics
4x25.0%AU$16.0m
1AD AdAlta
6.6xn/aAU$11.5m
BIT Biotron
10.4xn/aAU$17.1m
CYP Cynata Therapeutics
16.8x70.4%AU$38.8m
MDC Medlab Clinical
9.8x41.7%AU$15.1m

Price-To-Sales vs Peers: MDC is good value based on its Price-To-Sales Ratio (9.8x) compared to the peer average (13.1x).


Price to Sales Ratio vs Industry

How does MDC's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARX Aroa Biosurgery
3.6x20.1%US$146.13m
IMC Immuron
3.5x59.7%US$11.20m
ATH Alterity Therapeutics
4x25.0%US$10.40m
BNO Bionomics
2.4x-5.3%US$9.52m
MDC 9.8xIndustry Avg. 10.0xNo. of Companies8PS01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MDC is good value based on its Price-To-Sales Ratio (9.8x) compared to the Australian Biotechs industry average (12.8x)


Price to Sales Ratio vs Fair Ratio

What is MDC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.8x
Fair PS Ratio13x

Price-To-Sales vs Fair Ratio: MDC is good value based on its Price-To-Sales Ratio (9.8x) compared to the estimated Fair Price-To-Sales Ratio (13x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies